Literature DB >> 20512606

Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1.

Elahe Taherzadeh-Fard1, Carsten Saft, Stefan Wieczorek, Jörg T Epplen, Larissa Arning.   

Abstract

In previous candidate gene studies, associations of the age at onset (AO) in Huntington disease (HD) have been reported with genetic variations in the genes encoding adenosinergic A(2A) receptor (ADORA2A), human huntingtin-associated protein-1 (HAP1) and the single base excision repair enzyme, 7,8-dihydro-8-oxoguanine-DNA glycosylase (OGG1). Here, we sought to replicate these associations in an established study population of 419 unrelated German HD patients. AO was defined as the age at which the first motor signs of HD appeared, motor AO (mAO). For 215 patients, also information about the first behavioural or cognitive signs of HD was available, so that we also tested for an association with the earliest AO. No association was found with OGG1. For HAP1, we found modest evidence for association with the same risk allele as in the original sample and mAO. Yet, we replicated the previously reported association between the original ADORA2A polymorphism when using the earliest AO. Additionally, we identified new associations in the same gene, thus further supporting the potential contribution of ADORA2A to the pathogenesis of HD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512606     DOI: 10.1007/s10048-010-0248-3

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  20 in total

1.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

2.  Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds.

Authors:  J M Andresen; J Gayán; S S Cherny; D Brocklebank; G Alkorta-Aranburu; E A Addis; L R Cardon; D E Housman; N S Wexler
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

3.  OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells.

Authors:  Irina V Kovtun; Yuan Liu; Magnar Bjoras; Arne Klungland; Samuel H Wilson; Cynthia T McMurray
Journal:  Nature       Date:  2007-04-22       Impact factor: 49.962

Review 4.  The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis.

Authors:  S Boiteux; J P Radicella
Journal:  Arch Biochem Biophys       Date:  2000-05-01       Impact factor: 4.013

5.  DNA repair activity of 8-oxoguanine DNA glycosylase 1 (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326.

Authors:  K Janssen; K Schlink; W Götte; B Hippler; B Kaina; F Oesch
Journal:  Mutat Res       Date:  2001-08-09       Impact factor: 2.433

6.  A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.

Authors:  Claire-Marie Dhaenens; Sylvie Burnouf; Clémence Simonin; Edwige Van Brussel; Alain Duhamel; Luc Defebvre; Cécile Duru; Isabelle Vuillaume; Cécile Cazeneuve; Perrine Charles; Patrick Maison; Sabrina Debruxelles; Christophe Verny; Hélène Gervais; Jean-Philippe Azulay; Christine Tranchant; Anne-Catherine Bachoud-Levi; Alexandra Dürr; Luc Buée; Pierre Krystkowiak; Bernard Sablonnière; David Blum
Journal:  Neurobiol Dis       Date:  2009-07-08       Impact factor: 5.996

7.  A huntingtin-associated protein enriched in brain with implications for pathology.

Authors:  X J Li; S H Li; A H Sharp; F C Nucifora; G Schilling; A Lanahan; P Worley; S H Snyder; C A Ross
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

8.  No association between polymorphisms in the BDNF gene and age at onset in Huntington disease.

Authors:  Maren Mai; Amer D Akkad; Stefan Wieczorek; Carsten Saft; Jürgen Andrich; Peter H Kraus; Jörg T Epplen; Larissa Arning
Journal:  BMC Med Genet       Date:  2006-11-10       Impact factor: 2.103

9.  The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease.

Authors:  Patrick Weydt; Selma M Soyal; Cinzia Gellera; Stefano Didonato; Claus Weidinger; Hannes Oberkofler; G Bernhard Landwehrmeyer; Wolfgang Patsch
Journal:  Mol Neurodegener       Date:  2009-01-08       Impact factor: 14.195

10.  PGC-1alpha as modifier of onset age in Huntington disease.

Authors:  Elahe Taherzadeh-Fard; Carsten Saft; Jürgen Andrich; Stefan Wieczorek; Larissa Arning
Journal:  Mol Neurodegener       Date:  2009-02-06       Impact factor: 14.195

View more
  21 in total

1.  Autosomal dominant late-onset spinal motor neuronopathy is linked to a new locus on chromosome 22q11.2-q13.2.

Authors:  Sini Penttilä; Manu Jokela; Peter Hackman; Anna Maija Saukkonen; Jari Toivanen; Bjarne Udd
Journal:  Eur J Hum Genet       Date:  2012-04-25       Impact factor: 4.246

2.  Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.

Authors:  Eugen Kloster; Carsten Saft; Denis A Akkad; Jörg T Epplen; Larissa Arning
Journal:  J Mol Med (Berl)       Date:  2014-02       Impact factor: 4.599

Review 3.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

4.  Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease.

Authors:  Marco Orrú; Janaina Menezes Zanoveli; César Quiroz; Huu Phuc Nguyen; Xavier Guitart; Sergi Ferré
Journal:  Exp Neurol       Date:  2011-08-16       Impact factor: 5.330

5.  Age at onset in Huntington's disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7.

Authors:  Silke Metzger; Meiju Saukko; Hong Van Che; Liang Tong; Yvonne Puder; Olaf Riess; Huu Phuc Nguyen
Journal:  Hum Genet       Date:  2010-08-10       Impact factor: 4.132

6.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

Review 7.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

8.  Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.

Authors:  Xavier Guitart; Jordi Bonaventura; William Rea; Marco Orrú; Lucrezia Cellai; Ilaria Dettori; Felicita Pedata; Marc Brugarolas; Antonio Cortés; Vicent Casadó; Ching-Pang Chang; Manikandan Narayanan; Yijuang Chern; Sergi Ferré
Journal:  Neurobiol Dis       Date:  2016-08-24       Impact factor: 5.996

Review 9.  Metabolic Aspects of Adenosine Functions in the Brain.

Authors:  Mercedes Garcia-Gil; Marcella Camici; Simone Allegrini; Rossana Pesi; Maria Grazia Tozzi
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

10.  β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease.

Authors:  Angelica Vittori; Michael Orth; Raymund A C Roos; Tiago F Outeiro; Flaviano Giorgini; Edward J Hollox
Journal:  J Huntingtons Dis       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.